Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6851404,apparent volumes of distribution,Children had larger apparent volumes of distribution (1 l/kg) than adults (0.57 l/kg).,Digitoxin kinetics and renal excretion in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851404/),[l] / [kg],1,5868,DB01396,Digitoxin
,6851404,apparent volumes of distribution,Children had larger apparent volumes of distribution (1 l/kg) than adults (0.57 l/kg).,Digitoxin kinetics and renal excretion in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851404/),[l] / [kg],0.57,5869,DB01396,Digitoxin
,6851404,serum elimination t 1/2,Mean serum elimination t 1/2 was 6.4 days in children (3 to 11.2) and 8.2 days in adults (5.9 to 11.3).,Digitoxin kinetics and renal excretion in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851404/),d,6.4,5870,DB01396,Digitoxin
,6851404,serum elimination t 1/2,Mean serum elimination t 1/2 was 6.4 days in children (3 to 11.2) and 8.2 days in adults (5.9 to 11.3).,Digitoxin kinetics and renal excretion in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851404/),d,8.2,5871,DB01396,Digitoxin
,6851404,Total body clearance,Total body clearance was much greater in children (0.085 ml X min-1 X kg-1) than in adults (0.036 ml X min-1 X kg-1).,Digitoxin kinetics and renal excretion in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851404/),[ml] / [kg·min],0.085,5872,DB01396,Digitoxin
,6851404,Total body clearance,Total body clearance was much greater in children (0.085 ml X min-1 X kg-1) than in adults (0.036 ml X min-1 X kg-1).,Digitoxin kinetics and renal excretion in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851404/),[ml] / [kg·min],0.036,5873,DB01396,Digitoxin
,6851404,Peak serum concentrations,Peak serum concentrations of 23 to 50 ng/ml developed 90 to 120 min after the oral dose.,Digitoxin kinetics and renal excretion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851404/),[ng] / [ml],23 to 50,5874,DB01396,Digitoxin
,25544010,total run time,"A number of parameters were then varied in order to optimize the method, and a limit of quantitation (LOQ) at 0.2 ng/mL was reached with an injection volume of 5 μL, a total run time of 3 min, and 0.1 mL of rat plasma.",A sensitive method for digoxin determination using formate-adduct ion based on the effect of ionization enhancement in liquid chromatograph-mass spectrometer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544010/),min,3,8257,DB01396,Digitoxin
,9105544,plasma radioactivity,"In normal skin mice and rabbits, the plasma radioactivity peaked at 8 h (40.8 ng eq./ml) and at 12 h (34.0 ng eq./ml) after application, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),[eq·ng] / [ml],40.8,17098,DB01396,Digitoxin
,9105544,plasma radioactivity,"In normal skin mice and rabbits, the plasma radioactivity peaked at 8 h (40.8 ng eq./ml) and at 12 h (34.0 ng eq./ml) after application, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),[eq·ng] / [ml],34.0,17099,DB01396,Digitoxin
,9105544,Percutaneous absorption,"Percutaneous absorption of 14C-Am-80 was less than 2% of the dose for dogs, 34% for mice and 23% for rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,34,17100,DB01396,Digitoxin
,9105544,Percutaneous absorption,"Percutaneous absorption of 14C-Am-80 was less than 2% of the dose for dogs, 34% for mice and 23% for rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,23,17101,DB01396,Digitoxin
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,2.4,17102,DB01396,Digitoxin
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,7.2,17103,DB01396,Digitoxin
,9105544,half-lives,"After subcutaneous administration at a dose of 1 mg/kg to mice, dogs and rabbits, plasma levels of radioactivity peaked at 1, 4 and 4 h after dosing with a concentration of 614.0, 902.9 and 757.7 ng eq./ml and then it declined with half-lives of 2.4, 7.2 and 4.1 h, respectively.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),h,4.1,17104,DB01396,Digitoxin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,3.5,17105,DB01396,Digitoxin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,94.7,17106,DB01396,Digitoxin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,27.0,17107,DB01396,Digitoxin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,73.2,17108,DB01396,Digitoxin
,9105544,Urinary,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,43.5,17109,DB01396,Digitoxin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,3.5,17110,DB01396,Digitoxin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,94.7,17111,DB01396,Digitoxin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,27.0,17112,DB01396,Digitoxin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,73.2,17113,DB01396,Digitoxin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,43.5,17114,DB01396,Digitoxin
,9105544,fecal excretion,"Urinary and fecal excretion of radioactivity after subcutaneous administration at a dose of 1 mg/kg was 3.5 and 94.7% of the dose in dogs, 27.0 and 73.2% in mice and 43.5 and 45.6% in rabbits.","Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,45.6,17115,DB01396,Digitoxin
more,9105544,plasma protein binding,In vivo plasma protein binding of 14C-Am-80 and/or its radioactive metabolites was also found to be more than 98% in rats and dogs after subcutaneous administration of 14C-Am-80.,"Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9105544/),%,98,17116,DB01396,Digitoxin
,9278197,distribution,"The mean (s.d.) distribution and elimination half-lives, apparent volume of distribution and total body clearance were 1.1 +/- 0.4 h, 20.2 +/- 7.3 h, 13.1 +/- 5.8 l, and 17.6 +/- 10.8 ml min(-1), respectively.",Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278197/),h,1.1,17760,DB01396,Digitoxin
,9278197,apparent volume of distribution,"The mean (s.d.) distribution and elimination half-lives, apparent volume of distribution and total body clearance were 1.1 +/- 0.4 h, 20.2 +/- 7.3 h, 13.1 +/- 5.8 l, and 17.6 +/- 10.8 ml min(-1), respectively.",Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278197/),h,20.2,17761,DB01396,Digitoxin
,9278197,apparent volume of distribution,"The mean (s.d.) distribution and elimination half-lives, apparent volume of distribution and total body clearance were 1.1 +/- 0.4 h, 20.2 +/- 7.3 h, 13.1 +/- 5.8 l, and 17.6 +/- 10.8 ml min(-1), respectively.",Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278197/),l,13.1,17762,DB01396,Digitoxin
,9278197,total body clearance,"The mean (s.d.) distribution and elimination half-lives, apparent volume of distribution and total body clearance were 1.1 +/- 0.4 h, 20.2 +/- 7.3 h, 13.1 +/- 5.8 l, and 17.6 +/- 10.8 ml min(-1), respectively.",Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278197/),[ml] / [min],17.6,17763,DB01396,Digitoxin
,1269191,half-life,"In plasma, the time-course of radioactivity indicated a diminished absorption velocity of tritium compared to that of control subjects already reported and, after reaching of a pseudostate-equilibrium at 24 hr, an exponential decline with a mean half-life of 8.0 days.",Disposition of digitoxin in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269191/),d,8.0,23517,DB01396,Digitoxin
,346286,peak serum concentration,"With a single 600mg dose, peak serum concentration of the order of 10microgram/ml generally occur 2 hours after administration.",Clinical pharmacokinetics of rifampicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346286/),[μg] / [ml],10,29442,DB01396,Digitoxin
,346286,half-life,The half-life of rifampicin for this dose level is of the order of 2.5 hours.,Clinical pharmacokinetics of rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/346286/),h,2.5,29443,DB01396,Digitoxin
,438353,plasma concentrations,"On the other hand, in seven patients with renal failure, high dihydrodigitoxin plasma concentrations (8.9 +/- 0.9 ng/ml) were shown which were in a similar range as those of the parent compound (8.7 +/- 2.2 ng/ml) under a maintenance treatment with digitoxin.",Enhanced transformation of digitoxin to dihydrodigitoxin in humans with renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438353/),[ng] / [ml],8.9,31264,DB01396,Digitoxin
,438353,plasma concentrations,"On the other hand, in seven patients with renal failure, high dihydrodigitoxin plasma concentrations (8.9 +/- 0.9 ng/ml) were shown which were in a similar range as those of the parent compound (8.7 +/- 2.2 ng/ml) under a maintenance treatment with digitoxin.",Enhanced transformation of digitoxin to dihydrodigitoxin in humans with renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/438353/),[ng] / [ml],8.7,31265,DB01396,Digitoxin
,26012509,flow rate,The mobile phase was comprised of acetonitrile and 0.1mmolL(-1) aqueous lithium acetate mixed with 0.03% formic acid at the flow rate of 0.2mLmin(-1).,Determination of pseudoprotodioscin in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26012509/),1/[mlmin],0.2,36470,DB01396,Digitoxin
,26012509,bioavailability,PPD showed rapid excretion and with bioavailability of simply about 5.7% in rats.,Determination of pseudoprotodioscin in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26012509/),%,5.7,36471,DB01396,Digitoxin
,832589,concentration,"Digitoxin concentration, measured by radio-immunoassay, was significantly lower in 51 patients in chronic renal failure (23.2 +/- 7.8 mug/l) than in 29 patients in heart failure (26.5 +/- 7.3 mug/l), although both groups were on the same maintenance dose of 0.1 mg daily.",[Pharmacokinetics of digitoxin in chronic renal failure (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/832589/),μg,23,49849,DB01396,Digitoxin
,832589,elimination half-time,In patients in chronic renal failure elimination half-time was significantly shorter (5.7 +/- 0.9 days) than in healthy controls (7.6 +/- 1.6 days).,[Pharmacokinetics of digitoxin in chronic renal failure (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/832589/),d,5.7,49850,DB01396,Digitoxin
,832589,elimination half-time,In patients in chronic renal failure elimination half-time was significantly shorter (5.7 +/- 0.9 days) than in healthy controls (7.6 +/- 1.6 days).,[Pharmacokinetics of digitoxin in chronic renal failure (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/832589/),d,7.6,49851,DB01396,Digitoxin
,6748559,Plasma,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],0.64,50577,DB01396,Digitoxin
,6748559,Plasma,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],0.61,50578,DB01396,Digitoxin
,6748559,concentrations,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],13.9,50579,DB01396,Digitoxin
,6748559,concentrations,"Plasma AD concentrations were 0.64 +/- 0.22 ng/ml (mean +/- SD) before and 0.61 +/- 0.21 ng/ml during co-administration of N over 10-14 days, plasma DGT concentrations 13.9 +/- 4.1 ng/ml before and 13.7 +/- 4.5 ng/ml during co-administration of N over 4-6 weeks.",[Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6748559/),[ng] / [ml],13.7,50580,DB01396,Digitoxin
,530320,biological half-lives,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),h,0.12,52084,DB01396,Digitoxin
,530320,biological half-lives,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),h,0.48,52085,DB01396,Digitoxin
,530320,biological half-lives,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),h,20.4,52086,DB01396,Digitoxin
,530320,biological half-lives,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),h,0.11,52087,DB01396,Digitoxin
,530320,biological half-lives,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),h,0.43,52088,DB01396,Digitoxin
,530320,biological half-lives,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),h,31.8,52089,DB01396,Digitoxin
,530320,volume of distribution,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),,0.241,52090,DB01396,Digitoxin
,530320,volume of distribution,"The biological half-lives of dihydrodigitoxin (DH-DGT) and DGT are rather similar (0.12, 0.48, 20.4 h, and 0.11, 0.43, 31.8 h, respectively), whereas the volume of distribution of DH-DGT is about 1/10 from that of DGT (0.241 versus 2.581).",Pharmacokinetics of dihydrodigitoxin in the cat. A comparison with digitoxin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/530320/),,2.581,52091,DB01396,Digitoxin
above,18515196,extraction recovery,The mean extraction recovery from spiked plasma samples was above 80%.,Validation and application of a 96-well format solid-phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of digoxin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18515196/),%,80,56021,DB01396,Digitoxin
,3921586,excretory half-life,"Digoxin, the cardiac glycoside most frequently used in clinical practice in the United States, can be given orally or intravenously and has an excretory half-life of 36 to 48 hours in patients with serum creatinine and blood urea nitrogen values in the normal range.","Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921586/),h,36 to 48,60156,DB01396,Digitoxin
,3921586,half-life,"Since the drug is excreted predominantly by the kidney, the half-life is prolonged progressively with diminishing renal function, reaching about 5 days on average in patients who are essentially anephric.","Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921586/),d,5,60157,DB01396,Digitoxin
,3921586,Serum protein binding,"Serum protein binding of digoxin is only about 20%, and differs markedly in this regard from that of digitoxin, which is 97% bound by serum albumin at usual therapeutic levels.","Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921586/),%,20,60158,DB01396,Digitoxin
,3921586,half-life,Digitoxin is nearly completely absorbed from the normal gastrointestinal tract and has a half-life averaging 5 to 6 days in patients receiving usual doses irrespective of renal function.,"Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3921586/),d,5 to 6,60159,DB01396,Digitoxin
,1236603,biological half-lives,"4. The biological half-lives of tritiated ouabain, digoxin and digitoxin averaged 11 h, 2.5 days and 4.1 days, respectively, as determined by the terminal exponential elimination phase, in guinea-pigs.","Pharmacokinetics of tritiated ouabain, digoxin and digitoxin in guinea-pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1236603/),h,11,61235,DB01396,Digitoxin
,1236603,biological half-lives,"4. The biological half-lives of tritiated ouabain, digoxin and digitoxin averaged 11 h, 2.5 days and 4.1 days, respectively, as determined by the terminal exponential elimination phase, in guinea-pigs.","Pharmacokinetics of tritiated ouabain, digoxin and digitoxin in guinea-pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1236603/),d,2.5,61236,DB01396,Digitoxin
,1236603,biological half-lives,"4. The biological half-lives of tritiated ouabain, digoxin and digitoxin averaged 11 h, 2.5 days and 4.1 days, respectively, as determined by the terminal exponential elimination phase, in guinea-pigs.","Pharmacokinetics of tritiated ouabain, digoxin and digitoxin in guinea-pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1236603/),d,4.1,61237,DB01396,Digitoxin
,4002802,time for peak absorption,The time for peak absorption ranged between 1.5 and 6 hours on day 1 and 1.0 and 3 hours on day 28.,Pharmacokinetics and pharmacodynamics of muzolimine in chronic heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002802/),h,1.5 and 6,63569,DB01396,Digitoxin
,4002802,time for peak absorption,The time for peak absorption ranged between 1.5 and 6 hours on day 1 and 1.0 and 3 hours on day 28.,Pharmacokinetics and pharmacodynamics of muzolimine in chronic heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002802/),h,1.0,63570,DB01396,Digitoxin
,4002802,time for peak absorption,The time for peak absorption ranged between 1.5 and 6 hours on day 1 and 1.0 and 3 hours on day 28.,Pharmacokinetics and pharmacodynamics of muzolimine in chronic heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002802/),h,3,63571,DB01396,Digitoxin
,1164099,tissue/medium-ratio at equilibrium,"With digitoxin the tissue/medium-ratio at equilibrium was found to be 14 in guinea pigs and 8 in rats, with ouabain the corresponding values were 2 and 1.",[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),,14,69012,DB01396,Digitoxin
,1164099,tissue/medium-ratio at equilibrium,"With digitoxin the tissue/medium-ratio at equilibrium was found to be 14 in guinea pigs and 8 in rats, with ouabain the corresponding values were 2 and 1.",[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),,8,69013,DB01396,Digitoxin
,1164099,tissue/medium-ratio at equilibrium,"With digitoxin the tissue/medium-ratio at equilibrium was found to be 14 in guinea pigs and 8 in rats, with ouabain the corresponding values were 2 and 1.",[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),,2,69014,DB01396,Digitoxin
,1164099,tissue/medium-ratio at equilibrium,"With digitoxin the tissue/medium-ratio at equilibrium was found to be 14 in guinea pigs and 8 in rats, with ouabain the corresponding values were 2 and 1.",[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),,1,69015,DB01396,Digitoxin
,1164099,half lives,The half lives of compartment 1 (2.1-4.0 min) and those of compartment 2 (16.8-20.6 min) were similar with both glycosides and both species.,[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),min,2.1-4.0,69016,DB01396,Digitoxin
,1164099,half lives,The half lives of compartment 1 (2.1-4.0 min) and those of compartment 2 (16.8-20.6 min) were similar with both glycosides and both species.,[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),min,16.8-20.6,69017,DB01396,Digitoxin
,1164099,time for reaching the half maximum effect,The development and decline of the positive inotropic effect in guinea pig hearts exhibited a time course similar to that of the glycoside content in compartment 1: the time for reaching the half maximum effect was 3-4 min with ouabain and 5-6 min with digitoxin.,[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),min,3-4,69018,DB01396,Digitoxin
,1164099,time for reaching the half maximum effect,The development and decline of the positive inotropic effect in guinea pig hearts exhibited a time course similar to that of the glycoside content in compartment 1: the time for reaching the half maximum effect was 3-4 min with ouabain and 5-6 min with digitoxin.,[Pharmacokinetics and action of digitoxin and ouabain in the isolated hearts of guinea pigs and rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1164099/),min,5-6,69019,DB01396,Digitoxin
,6489430,systemic clearance,"After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days.",Pharmacokinetics and bioavailability of digitoxin by a specific assay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489430/),[ml] / [min],2.44,73332,DB01396,Digitoxin
,6489430,volume of distribution,"After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days.",Pharmacokinetics and bioavailability of digitoxin by a specific assay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489430/),[l] / [kg],0.47,73333,DB01396,Digitoxin
,6489430,elimination half-life,"After intravenous administration, the mean systemic clearance was 2.44 ml/min; the volume of distribution was 0.47 l/kg; and the elimination half-life was 6.5 days.",Pharmacokinetics and bioavailability of digitoxin by a specific assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489430/),d,6.5,73334,DB01396,Digitoxin
,6489430,elimination half-life,"After oral administration, the elimination half-life was 5.8 days.",Pharmacokinetics and bioavailability of digitoxin by a specific assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489430/),d,5.8,73335,DB01396,Digitoxin
,6489430,bioavailability,The bioavailability was 81.5% using the specific assay.,Pharmacokinetics and bioavailability of digitoxin by a specific assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489430/),%,81.5,73336,DB01396,Digitoxin
,6489430,bioavailability,"Using a non-specific, direct serum digitoxin radioimmunoassay the bioavailability was 98.0%.",Pharmacokinetics and bioavailability of digitoxin by a specific assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6489430/),%,98.0,73337,DB01396,Digitoxin
,947651,Serum protein binding,"Serum protein binding of digitoxin was lower (p less than 0.05) in 7 patients with nephrotic syndrome (96.2%, SD 1.4) than in 51 control patients (97.3%, SD 0.5).","Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),%,96.2,80964,DB01396,Digitoxin
,947651,Serum protein binding,"Serum protein binding of digitoxin was lower (p less than 0.05) in 7 patients with nephrotic syndrome (96.2%, SD 1.4) than in 51 control patients (97.3%, SD 0.5).","Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),%,97.3,80965,DB01396,Digitoxin
,947651,protein binding,Urine protein binding of digitoxin was 60.1% in the 6 nephrotic patients in whom it was determined.,"Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),%,60.1,80966,DB01396,Digitoxin
,947651,T/2,Mean T/2 of serum elimation was 4.8 days and 8.1 days in 5 control subjects (p less than 0.05).,"Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),d,4.8,80967,DB01396,Digitoxin
,947651,T/2,Mean T/2 of serum elimation was 4.8 days and 8.1 days in 5 control subjects (p less than 0.05).,"Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),d,8.1,80968,DB01396,Digitoxin
,947651,urine concentration T/2,The urine concentration T/2 with a mean value of 5.0 days was not significantly different from controls (7.2 days).,"Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),d,5.0,80969,DB01396,Digitoxin
,947651,urine concentration T/2,The urine concentration T/2 with a mean value of 5.0 days was not significantly different from controls (7.2 days).,"Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),d,7.2,80970,DB01396,Digitoxin
,947651,cumulative renal exeretion,The cumulative renal exeretion was higher in the nephrotic group (23.2% of dose) than in controls (15.8%) for 8 days.,"Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),%,23.2,80971,DB01396,Digitoxin
,947651,cumulative renal exeretion,The cumulative renal exeretion was higher in the nephrotic group (23.2% of dose) than in controls (15.8%) for 8 days.,"Studies on digitalis. Influence of nephrotic syndrome on protein binding, pharmacokinetics, and renal excretion of digitoxin and cardioactive metabolites. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/947651/),%,15.8,80972,DB01396,Digitoxin
,3946177,clearance,"Following administration of digitoxin, 1 mg intravenously, the pharmacokinetics of this glycoside were studied in eight healthy volunteers and in eight patients with hepatorenal insufficiency (mean creatinine clearance 19.6 +/- 2.9 ml/min; antipyrine clearance 25.6 +/- 3.2 ml/min; means +/- SEM).",Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),[ml] / [min],25.6,93446,DB01396,Digitoxin
,3946177,Plasma protein binding,Plasma protein binding of digitoxin (means +/- SEM) was 95.1 +/- 0.7% in the patients and 95.6 +/- 1.2% in the volunteers (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),%,95.1,93447,DB01396,Digitoxin
,3946177,Plasma protein binding,Plasma protein binding of digitoxin (means +/- SEM) was 95.1 +/- 0.7% in the patients and 95.6 +/- 1.2% in the volunteers (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),%,95.6,93448,DB01396,Digitoxin
,3946177,Total body clearance,Total body clearance of digitoxin was 0.0530 +/- 0.0040 ml/min/kg of body weight in the patients and 0.0547 +/- 0.0043 ml/min/kg of body weight in the healthy subjects (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),[ml] / [kg·min],0.0530,93449,DB01396,Digitoxin
,3946177,Total body clearance,Total body clearance of digitoxin was 0.0530 +/- 0.0040 ml/min/kg of body weight in the patients and 0.0547 +/- 0.0043 ml/min/kg of body weight in the healthy subjects (NS).,Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),[ml] / [kg·min],0.0547,93450,DB01396,Digitoxin
,3946177,elimination half-lives,"When elimination half-lives of the patients and the volunteers were compared, there was also no significant difference (7.0 +/- 0.77 days in the patient group and 7.8 +/- 0.8 days in the volunteers).",Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),d,7.0,93451,DB01396,Digitoxin
,3946177,elimination half-lives,"When elimination half-lives of the patients and the volunteers were compared, there was also no significant difference (7.0 +/- 0.77 days in the patient group and 7.8 +/- 0.8 days in the volunteers).",Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3946177/),d,7.8,93452,DB01396,Digitoxin
,22784612,Cmax,"Therefore, median values (min; max) were calculated as follows: Cmax = 0.39 (0.15; 1.81) ng/ml, tmax = 7.0 (3.0; 36.0) h, T1/2 = 5.2 (0.8; 23.6) h, AUC0-36h = 4.2 (0.8; 11.1) ng/ml×h, AUC0-∞ = 5.8 (1.8; 13.1) ng/ml×h.","Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784612/),[ng] / [ml],0.39,129008,DB01396,Digitoxin
,22784612,tmax,"Therefore, median values (min; max) were calculated as follows: Cmax = 0.39 (0.15; 1.81) ng/ml, tmax = 7.0 (3.0; 36.0) h, T1/2 = 5.2 (0.8; 23.6) h, AUC0-36h = 4.2 (0.8; 11.1) ng/ml×h, AUC0-∞ = 5.8 (1.8; 13.1) ng/ml×h.","Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784612/),h,7.0,129009,DB01396,Digitoxin
,22784612,T1/2,"Therefore, median values (min; max) were calculated as follows: Cmax = 0.39 (0.15; 1.81) ng/ml, tmax = 7.0 (3.0; 36.0) h, T1/2 = 5.2 (0.8; 23.6) h, AUC0-36h = 4.2 (0.8; 11.1) ng/ml×h, AUC0-∞ = 5.8 (1.8; 13.1) ng/ml×h.","Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784612/),h,5.2,129010,DB01396,Digitoxin
,22784612,AUC0-36h,"Therefore, median values (min; max) were calculated as follows: Cmax = 0.39 (0.15; 1.81) ng/ml, tmax = 7.0 (3.0; 36.0) h, T1/2 = 5.2 (0.8; 23.6) h, AUC0-36h = 4.2 (0.8; 11.1) ng/ml×h, AUC0-∞ = 5.8 (1.8; 13.1) ng/ml×h.","Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784612/),[ng] / [h·ml],4.2,129011,DB01396,Digitoxin
,22784612,AUC0-∞,"Therefore, median values (min; max) were calculated as follows: Cmax = 0.39 (0.15; 1.81) ng/ml, tmax = 7.0 (3.0; 36.0) h, T1/2 = 5.2 (0.8; 23.6) h, AUC0-36h = 4.2 (0.8; 11.1) ng/ml×h, AUC0-∞ = 5.8 (1.8; 13.1) ng/ml×h.","Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784612/),[ng] / [h·ml],5.8,129012,DB01396,Digitoxin
,22784612,Cmax,"DLSL reached Cmax of 28 ng/ml and 1,980 ng/ml for digoxin and digitoxin, respectively.","Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784612/),[ng] / [ml],28,129013,DB01396,Digitoxin
,22784612,Cmax,"DLSL reached Cmax of 28 ng/ml and 1,980 ng/ml for digoxin and digitoxin, respectively.","Cardiovascular effects, pharmacokinetics and cross-reactivity in digitalis glycoside immunoassays of an antidiarrheal uzara root extract. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784612/),[ng] / [ml],"1,980",129014,DB01396,Digitoxin
,1143356,half-life,"In plasma, the concentrations of total radioactivity are reduced in pretreated animals to about 20% of tritium levels in control rats, while the half-life of radioactivity in both groups is almost identical, 2.9 days in pretreated rats and 2.8 days in controls.",Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1143356/),d,2.9,131936,DB01396,Digitoxin
,1143356,half-life,"In plasma, the concentrations of total radioactivity are reduced in pretreated animals to about 20% of tritium levels in control rats, while the half-life of radioactivity in both groups is almost identical, 2.9 days in pretreated rats and 2.8 days in controls.",Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1143356/),d,2.8,131937,DB01396,Digitoxin
,7424564,Clearance,"Clearance values of 135--185 and 190--200 ml/min were obtained for amitriptyline and nortriptyline, respectively.",Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],135--185,147714,DB01396,Digitoxin
,7424564,Clearance,"Clearance values of 135--185 and 190--200 ml/min were obtained for amitriptyline and nortriptyline, respectively.",Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],190,147715,DB01396,Digitoxin
,7424564,clearance,A clearance of 140 ml/min was obtained in a uremic patient with AV block II due to digitoxin intoxication.,Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],140,147716,DB01396,Digitoxin
,8243505,clearance,Pharmacokinetic profile and urinary excretion of digitoxin and 4 metabolites were investigated in 9 patients with biopsy confirmed liver cirrhosis (median antipyrine clearance 20.0 +/- 5.4 ml/min; X +/- SEM) and were compared with that of 8 healthy volunteers (antipyrine clearance 36.9 +/- 4.9 ml/min) following intravenous and p.o. administration of 1 mg digitoxin.,Digitoxin and its metabolites in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [min],20.0,150963,DB01396,Digitoxin
,8243505,clearance,Pharmacokinetic profile and urinary excretion of digitoxin and 4 metabolites were investigated in 9 patients with biopsy confirmed liver cirrhosis (median antipyrine clearance 20.0 +/- 5.4 ml/min; X +/- SEM) and were compared with that of 8 healthy volunteers (antipyrine clearance 36.9 +/- 4.9 ml/min) following intravenous and p.o. administration of 1 mg digitoxin.,Digitoxin and its metabolites in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [min],36.9,150964,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.017,150965,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.011,150966,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00340,150967,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00223,150968,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00006,150969,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00016,150970,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00041,150971,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00088,150972,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),[ml] / [kg·min],0.00135,150973,DB01396,Digitoxin
,8243505,Renal clearance,"Renal clearance of digitoxin was 0.017 +/- 0.005 ml/min/kg in the patient group and 0.011 +/- 0.002 ml/min/kg in the volunteers (NS); it was 0.00340 +/- 0.00047 ml/min/kg and 0.00223 +/- 0.00039 ml/min/kg, respectively for digitoxigenin-bis-digitoxoside (NS), 0.00006 +/- 0.00001 ml/min/kg and 0.00016 +/- 0.00005 ml/min/kg for digitoxigenin-mono-digitoxoside (P < 0.05), 0.00041 +/- 0.00013 ml/min/kg and 0.00088 +/- 0.00032 ml/min/kg for digitoxigenin (P < 0.05), 0.00135 +/- 0.00049 ml/min/kg and 0.00113 +/- 0.00042 ml/min/kg for digoxin (NS).",Digitoxin and its metabolites in patients with liver cirrhosis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8243505/),,0.00113,150974,DB01396,Digitoxin
,2327624,excretion,"In 10 group-B dogs given 3H-digitoxin (groups 1B, 2B, and 4B), the excretion of total radioactivity in urine and bile was 15 to 20 and 7% of the dose, respectively in the first 24 hours.",Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327624/),%,15 to 20,153682,DB01396,Digitoxin
,2327624,excretion,"In 10 group-B dogs given 3H-digitoxin (groups 1B, 2B, and 4B), the excretion of total radioactivity in urine and bile was 15 to 20 and 7% of the dose, respectively in the first 24 hours.",Influence of induced cholestasis on pharmacokinetics of digoxin and digitoxin in dogs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2327624/),%,7,153683,DB01396,Digitoxin
,26093244,flow rate,"After liquid-liquid extraction with ethyl acetate, chromatographic separation was performed on a C18 column with a 13 min gradient elution using 0.1% formic acid and acetonitrile as mobile phase at a flow rate of 0.3 mL/min.","A validated LC-MS/MS assay for the simultaneous determination of periplocin and its two metabolites, periplocymarin and periplogenin in rat plasma: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26093244/),[ml] / [min],0.3,158131,DB01396,Digitoxin
higher,26093244,recoveries,The mean recoveries of the analytes and IS were higher than 67.7%.,"A validated LC-MS/MS assay for the simultaneous determination of periplocin and its two metabolites, periplocymarin and periplogenin in rat plasma: Application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26093244/),%,67.7,158132,DB01396,Digitoxin
,2609697,Plasma levels,Plasma levels between 0 and 84.2 ng.,[Therapeutic drug monitoring of digitoxin--results of 3 years' experience]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609697/),ng,0 and 84.2,171574,DB01396,Digitoxin
,6628525,mean plasma concentration,The mean plasma concentration 24 h after 0.5 mg i.v. was 5.2 ng X ml-1.,On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628525/),[ng] / [ml],5.2,173706,DB01396,Digitoxin
,6628525,elimination half-life,Following an open two-compartment model a mean elimination half-life of 60.5 h (24.9 to 103.5 h) and a mean volume of distribution (Vdarea) of 66.91 (31.8 to 109.61) were calculated.,On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628525/),h,60.5,173707,DB01396,Digitoxin
,6628525,volume of distribution (Vdarea),Following an open two-compartment model a mean elimination half-life of 60.5 h (24.9 to 103.5 h) and a mean volume of distribution (Vdarea) of 66.91 (31.8 to 109.61) were calculated.,On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628525/),,66.91,173708,DB01396,Digitoxin
,6628525,Absorption,Absorption calculated by comparison of the AUC0-infinity-values amounted to 99%.,On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628525/),%,99,173709,DB01396,Digitoxin
,6628525,total body clearance,After pengitoxin 0.5 mg i.v. total body clearance and renal clearance were 13.3 ml X min-1 (7.0 to 18.6 ml X min-1) and 3.0 ml X min-1 (1.9 to 3.9 ml X min-1) respectively.,On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628525/),[ml] / [min],13.3,173710,DB01396,Digitoxin
,6628525,renal clearance,After pengitoxin 0.5 mg i.v. total body clearance and renal clearance were 13.3 ml X min-1 (7.0 to 18.6 ml X min-1) and 3.0 ml X min-1 (1.9 to 3.9 ml X min-1) respectively.,On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628525/),[ml] / [min],3.0,173711,DB01396,Digitoxin
,3512148,plasma concentrations,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[ng] / [ml],13.6,178053,DB01396,Digitoxin
,3512148,plasma concentrations,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[ng] / [ml],19.7,178054,DB01396,Digitoxin
,3512148,renal excretion,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[μg] / [24·h],16.1,178055,DB01396,Digitoxin
,3512148,renal excretion,"Mean (+/- SD) digitoxin plasma concentrations and renal excretion increased from 13.6 +/- 2.2 ng/ml and 16.1 +/- 5.8 micrograms/24 hours before dosing to 19.7 +/- 3.1 ng/ml and 23.4 +/- 4.9 micrograms/24 hours, respectively, during quinidine dosing for 32 days.",Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),[μg] / [24·h],23.4,178056,DB01396,Digitoxin
,3512148,elimination t1/2,The elimination t1/2 was prolonged from 150.3 +/- 20.6 to 202.6 +/- 37.5 hours.,Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),h,150.3,178057,DB01396,Digitoxin
,3512148,elimination t1/2,The elimination t1/2 was prolonged from 150.3 +/- 20.6 to 202.6 +/- 37.5 hours.,Effects of quinidine on pharmacokinetics and pharmacodynamics of digitoxin achieving steady-state conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512148/),h,202.6,178058,DB01396,Digitoxin
,10074832,half-life,Mean digitoxin half-life was 25.2 days.,[Prolonged half-life of digitoxin in the elderly]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10074832/),d,25.2,180082,DB01396,Digitoxin
,598419,percentage absorption,"By comparison of the radioactivity excreted in urine following the 2 routes of 16-acetate administration, the percentage absorption was calculated to be 88.5%.",Pharmacokinetic investigations in man of two acetyl derivatives of 16alpha-gitoxin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598419/),%,88.5,180643,DB01396,Digitoxin
,94409,half-time,Median serum digitoxin half-time was 5.7 hr.,Correlation between pharmacokinetics and intropic and electrophysiologic responses to digitoxin in the intact dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94409/),h,5.7,182551,DB01396,Digitoxin
,7439268,steady state plasma digoxin concentration,The dosing schedule resulted in correct digitalization expressed as a steady state plasma digoxin concentration in the therapeutic range (0.5-2.0 ng/ml) in 25 out of 27 patients (93%).,"Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439268/),[ng] / [ml],0.5-2.0,188356,DB01396,Digitoxin
,2702965,clearance,Mean antipyrine clearance (parameter of oxidative liver function) was 49.7 +/- 6.0 ml min-1 in the volunteers and 22.0 +/- 2.9 ml min-1 in the patients.,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [min],49.7,188697,DB01396,Digitoxin
,2702965,clearance,Mean antipyrine clearance (parameter of oxidative liver function) was 49.7 +/- 6.0 ml min-1 in the volunteers and 22.0 +/- 2.9 ml min-1 in the patients.,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [min],22.0,188698,DB01396,Digitoxin
,2702965,Plasma protein binding,Plasma protein binding of digitoxin (PPB) was 95.0 +/- 1.1% in the patients and 96.7 +/- 0.6% in the healthy subjects (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),%,95.0,188699,DB01396,Digitoxin
,2702965,Plasma protein binding,Plasma protein binding of digitoxin (PPB) was 95.0 +/- 1.1% in the patients and 96.7 +/- 0.6% in the healthy subjects (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),%,96.7,188700,DB01396,Digitoxin
,2702965,Total body clearance of digitoxin (Cltot),Total body clearance of digitoxin (Cltot) was 0.0728 +/- 0.0120 ml min-1 kg-1 in the patients and 0.0615 +/- 0.0027 ml min-1 kg-1 in normals (n.s.].,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [kg·min],0.0728,188701,DB01396,Digitoxin
,2702965,Total body clearance of digitoxin (Cltot),Total body clearance of digitoxin (Cltot) was 0.0728 +/- 0.0120 ml min-1 kg-1 in the patients and 0.0615 +/- 0.0027 ml min-1 kg-1 in normals (n.s.].,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ml] / [kg·min],0.0615,188702,DB01396,Digitoxin
,2702965,steady state plasma levels (Css),Mean steady state plasma levels (Css) of the patients were 18.3 +/- 4.7 ng ml-1 and 15.8 +/- 1.3 ng ml-1 in the normals (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ng] / [ml],18.3,188703,DB01396,Digitoxin
,2702965,steady state plasma levels (Css),Mean steady state plasma levels (Css) of the patients were 18.3 +/- 4.7 ng ml-1 and 15.8 +/- 1.3 ng ml-1 in the normals (n.s.).,Digitoxin in patients with hepatorenal insufficiency after repeated oral administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702965/),[ng] / [ml],15.8,188704,DB01396,Digitoxin
,8321833,limit of detection,The limit of detection was 0.1 microgram/mL and the assay was linear over a 0.6-28 micrograms/mL range of Fab fragments.,Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321833/),[μg] / [ml],0.1,191017,DB01396,Digitoxin
,8321833,Fab elimination half-life,The Fab elimination half-life was 12.1 hr.,Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321833/),h,12.1,191018,DB01396,Digitoxin
,8321833,Steady-state volume of distribution,"Steady-state volume of distribution and total-body clearance were 10.8 L and 23.4 mL/min, respectively.",Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321833/),l,10.8,191019,DB01396,Digitoxin
,8321833,total-body clearance,"Steady-state volume of distribution and total-body clearance were 10.8 L and 23.4 mL/min, respectively.",Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321833/),[ml] / [min],23.4,191020,DB01396,Digitoxin
,914999,intrinsic association constant,Selected antiserum from sheep immunized and boosted with a digoxin-serum albumin conjugate contained antibodies that cross-reacted with digitoxin with an average intrinsic association constant of 1.4 x 10(10) M(-1) as determined by equilibrium dialysis.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),1/[M],1.4 x 10(10),199371,DB01396,Digitoxin
,914999,k(f),Rapid second-order association kinetics (k(f) = 3.7 x 10(6) M(-1) per s) and slow dissociation kinetics (k(r) = 1.9 x 10(-4) per s) were documented for the antibody-digitoxin complex.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),1/[M·s],3.7 x 10(6),199372,DB01396,Digitoxin
,914999,k(r),Rapid second-order association kinetics (k(f) = 3.7 x 10(6) M(-1) per s) and slow dissociation kinetics (k(r) = 1.9 x 10(-4) per s) were documented for the antibody-digitoxin complex.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),1/[s],1.9 x 10(-4),199373,DB01396,Digitoxin
,914999,elimination half-life,"Unlike common laboratory animals previously studied, the rhesus monkey was found to have a prolonged elimination half-life, estimated at 135 and 118 h by radioimmunoassay and [(3)H]digitoxin measurements, respectively, similar to man and thus providing a clinically relevant experimental model.",Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),h,135,199374,DB01396,Digitoxin
,914999,elimination half-life,"Unlike common laboratory animals previously studied, the rhesus monkey was found to have a prolonged elimination half-life, estimated at 135 and 118 h by radioimmunoassay and [(3)H]digitoxin measurements, respectively, similar to man and thus providing a clinically relevant experimental model.",Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),h,118,199375,DB01396,Digitoxin
,914999,t((1/2)),Intravenous administration of 2 mol of specific Fab fragments per mole of digitoxin 6 h after 0.2 mg of digitoxin produced a rapid 4.3-fold increase in plasma total digitoxin concentration followed by a rapid fall (t((1/2)) 4 h) accompanied by a 14-fold enhancement of urinary digitoxin excretion over control values during the 6-h period after Fab was given.,Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914999/),h,4,199376,DB01396,Digitoxin
,914188,t1/2,"The mean t1/2 of digitoxin for i.v. administration was 9.5 +/- 0.9 days, for oral administration of tablets 7.4 +/- 0.5 days and for dragées 9.7 +/- 2.0 days.",[The biological availability of digitoxin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914188/),d,9.5,205093,DB01396,Digitoxin
,914188,t1/2,"The mean t1/2 of digitoxin for i.v. administration was 9.5 +/- 0.9 days, for oral administration of tablets 7.4 +/- 0.5 days and for dragées 9.7 +/- 2.0 days.",[The biological availability of digitoxin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914188/),d,7.4,205094,DB01396,Digitoxin
,914188,t1/2,"The mean t1/2 of digitoxin for i.v. administration was 9.5 +/- 0.9 days, for oral administration of tablets 7.4 +/- 0.5 days and for dragées 9.7 +/- 2.0 days.",[The biological availability of digitoxin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914188/),d,9.7,205095,DB01396,Digitoxin
,914188,absolute bioavailability,The mean absolute bioavailability of digitoxin-dragées amounted to 82-88 percent and the relative bioavailability of digitoxin-tablets to 84-93 percent.,[The biological availability of digitoxin]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914188/),%,82-88,205096,DB01396,Digitoxin
,914188,relative bioavailability,The mean absolute bioavailability of digitoxin-dragées amounted to 82-88 percent and the relative bioavailability of digitoxin-tablets to 84-93 percent.,[The biological availability of digitoxin]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/914188/),%,84-93,205097,DB01396,Digitoxin
,7461023,T1/2 beta,Plasma radioactivity declined with a T1/2 beta between 77 and 234 h (mean 138 h) in the case of digitoxin and with a T1/2 beta between 9.2 and 38.6 h (mean 23.5 h) for digoxin.,Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461023/),h,77 and 234,212990,DB01396,Digitoxin
,7461023,T1/2 beta,Plasma radioactivity declined with a T1/2 beta between 77 and 234 h (mean 138 h) in the case of digitoxin and with a T1/2 beta between 9.2 and 38.6 h (mean 23.5 h) for digoxin.,Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461023/),h,138,212991,DB01396,Digitoxin
,7461023,T1/2 beta,Plasma radioactivity declined with a T1/2 beta between 77 and 234 h (mean 138 h) in the case of digitoxin and with a T1/2 beta between 9.2 and 38.6 h (mean 23.5 h) for digoxin.,Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461023/),h,9.2 and 38.6,212992,DB01396,Digitoxin
,7461023,T1/2 beta,Plasma radioactivity declined with a T1/2 beta between 77 and 234 h (mean 138 h) in the case of digitoxin and with a T1/2 beta between 9.2 and 38.6 h (mean 23.5 h) for digoxin.,Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7461023/),h,23.5,212993,DB01396,Digitoxin
,4065189,bioavailability,"However, the mean bioavailability of unchanged bisdigitoxoside was only 56.3% indicating that substantial metabolism occurred prior to entry into the systemic circulation.",Bioavailability of the bis- and monodigitoxosides of digitoxigenin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4065189/),%,56.3,213261,DB01396,Digitoxin
,15176651,Maximal apparent serum concentrations,Maximal apparent serum concentrations of digitoxin between 198.0 microg/l and 919.8 microg/l (therapeutic range: 10-25 microg/l) occurred at 4-8 hours after administration.,Interference of Uzara glycosides in assays of digitalis glycosides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176651/),[μg] / [l],198.0,216124,DB01396,Digitoxin
,15176651,Maximal apparent serum concentrations,Maximal apparent serum concentrations of digitoxin between 198.0 microg/l and 919.8 microg/l (therapeutic range: 10-25 microg/l) occurred at 4-8 hours after administration.,Interference of Uzara glycosides in assays of digitalis glycosides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176651/),[μg] / [l],919.8,216125,DB01396,Digitoxin
,15176651,terminal half-life,The terminal half-life of the glycosides was 8.87 +/- 2.20 hours.,Interference of Uzara glycosides in assays of digitalis glycosides. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176651/),h,8.87,216126,DB01396,Digitoxin
,15176651,maximal apparent serum concentrations,"For digoxin, maximal apparent serum concentrations ranged between 1.4 microg/l and 6.34 microg/l (therapeutic range: 0.9-2.0 microg/l) at 6 hours post dosing.",Interference of Uzara glycosides in assays of digitalis glycosides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176651/),[μg] / [l],1.4,216127,DB01396,Digitoxin
,15176651,maximal apparent serum concentrations,"For digoxin, maximal apparent serum concentrations ranged between 1.4 microg/l and 6.34 microg/l (therapeutic range: 0.9-2.0 microg/l) at 6 hours post dosing.",Interference of Uzara glycosides in assays of digitalis glycosides. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15176651/),[μg] / [l],6.34,216128,DB01396,Digitoxin
,3772737,t1/2,"After a single i.v. injection of equimolar doses, 16AG and PAG showed similar mean kinetic parameters: t1/2 = 51.6 hr (16AG) and 60.8 hr (PAG), CL = 11.7 ml min-1 (16AG) and 12.7 ml min-1 (PAG), CLR = 4.1 ml min-1 (16AG) and 4.2 ml min-1 (PAG).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),h,51.6,222645,DB01396,Digitoxin
,3772737,t1/2,"After a single i.v. injection of equimolar doses, 16AG and PAG showed similar mean kinetic parameters: t1/2 = 51.6 hr (16AG) and 60.8 hr (PAG), CL = 11.7 ml min-1 (16AG) and 12.7 ml min-1 (PAG), CLR = 4.1 ml min-1 (16AG) and 4.2 ml min-1 (PAG).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),h,60.8,222646,DB01396,Digitoxin
,3772737,CL,"After a single i.v. injection of equimolar doses, 16AG and PAG showed similar mean kinetic parameters: t1/2 = 51.6 hr (16AG) and 60.8 hr (PAG), CL = 11.7 ml min-1 (16AG) and 12.7 ml min-1 (PAG), CLR = 4.1 ml min-1 (16AG) and 4.2 ml min-1 (PAG).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),[ml] / [min],11.7,222647,DB01396,Digitoxin
,3772737,CL,"After a single i.v. injection of equimolar doses, 16AG and PAG showed similar mean kinetic parameters: t1/2 = 51.6 hr (16AG) and 60.8 hr (PAG), CL = 11.7 ml min-1 (16AG) and 12.7 ml min-1 (PAG), CLR = 4.1 ml min-1 (16AG) and 4.2 ml min-1 (PAG).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),[ml] / [min],12.7,222648,DB01396,Digitoxin
,3772737,CLR,"After a single i.v. injection of equimolar doses, 16AG and PAG showed similar mean kinetic parameters: t1/2 = 51.6 hr (16AG) and 60.8 hr (PAG), CL = 11.7 ml min-1 (16AG) and 12.7 ml min-1 (PAG), CLR = 4.1 ml min-1 (16AG) and 4.2 ml min-1 (PAG).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),[ml] / [min],4.1,222649,DB01396,Digitoxin
,3772737,CLR,"After a single i.v. injection of equimolar doses, 16AG and PAG showed similar mean kinetic parameters: t1/2 = 51.6 hr (16AG) and 60.8 hr (PAG), CL = 11.7 ml min-1 (16AG) and 12.7 ml min-1 (PAG), CLR = 4.1 ml min-1 (16AG) and 4.2 ml min-1 (PAG).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),[ml] / [min],4.2,222650,DB01396,Digitoxin
,3772737,half-life,The 16AG was absorbed from solution with a mean half-life of 0.2 hr to an extent of 98.6%.,On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),h,0.2,222651,DB01396,Digitoxin
,3772737,urinary excretion/Ae (0,"The mean urinary excretion/Ae (0,4)/of 16AG amounted to 24.6% (A1), 20.8% (A2) and 28.1% (A3).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),%,24.6,222652,DB01396,Digitoxin
,3772737,urinary excretion/Ae (0,"The mean urinary excretion/Ae (0,4)/of 16AG amounted to 24.6% (A1), 20.8% (A2) and 28.1% (A3).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),%,20.8,222653,DB01396,Digitoxin
,3772737,urinary excretion/Ae (0,"The mean urinary excretion/Ae (0,4)/of 16AG amounted to 24.6% (A1), 20.8% (A2) and 28.1% (A3).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),%,28.1,222654,DB01396,Digitoxin
,3772737,bioavailability,"On the basis of AUC values, the mean bioavailability of PAG from either tablet formulation amounted to 79.6% (B2) and 89.6% (B3).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),%,79.6,222655,DB01396,Digitoxin
,3772737,bioavailability,"On the basis of AUC values, the mean bioavailability of PAG from either tablet formulation amounted to 79.6% (B2) and 89.6% (B3).",On the pharmacokinetics of 16-acetyl-gitoxin and its bioavailability from pengitoxin-containing tablet formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3772737/),%,89.6,222656,DB01396,Digitoxin
,15734156,m/,"The /specific ions monitored were m/z 819.50 for Rg3, m/z 657.35 for Rh2, m/z 495.40 for ppd and m/z 799.55 for the internal standard (digitoxin).",High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734156/),,819.50,223842,DB01396,Digitoxin
,15734156,m/z,"The /specific ions monitored were m/z 819.50 for Rg3, m/z 657.35 for Rh2, m/z 495.40 for ppd and m/z 799.55 for the internal standard (digitoxin).",High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734156/),,657.35,223843,DB01396,Digitoxin
,15734156,m/z,"The /specific ions monitored were m/z 819.50 for Rg3, m/z 657.35 for Rh2, m/z 495.40 for ppd and m/z 799.55 for the internal standard (digitoxin).",High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734156/),,495.40,223844,DB01396,Digitoxin
,15734156,recoveries,"The mean recoveries for Rg3, Rh2 and ppd were 77.85, 82.65 and 98.33%, respectively using 0.1 ml plasma for extraction.",High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734156/),%,77.85,223845,DB01396,Digitoxin
,15734156,recoveries,"The mean recoveries for Rg3, Rh2 and ppd were 77.85, 82.65 and 98.33%, respectively using 0.1 ml plasma for extraction.",High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734156/),%,82.65,223846,DB01396,Digitoxin
,15734156,recoveries,"The mean recoveries for Rg3, Rh2 and ppd were 77.85, 82.65 and 98.33%, respectively using 0.1 ml plasma for extraction.",High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15734156/),%,98.33,223847,DB01396,Digitoxin
,1242671,half-life of label,The half-life of label in the plasma was 8.5 +/- 1 (i.v.) and 8.8 +/- 1 (p.o.) days.,[Studies on metabolism and pharmacokinetics of alpha-acetyldigitoxin in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1242671/),d,8.5,226799,DB01396,Digitoxin
,1242671,half-life of label,The half-life of label in the plasma was 8.5 +/- 1 (i.v.) and 8.8 +/- 1 (p.o.) days.,[Studies on metabolism and pharmacokinetics of alpha-acetyldigitoxin in man (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1242671/),d,8.8,226800,DB01396,Digitoxin
,1242671,volatile content,The volatile content of plasma radioactivity was 4.07 +/- 0.1% (i.v.) and 6.78 +/- 0.2% (p.o.).,[Studies on metabolism and pharmacokinetics of alpha-acetyldigitoxin in man (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1242671/),%,4.07,226801,DB01396,Digitoxin
,1242671,volatile content,The volatile content of plasma radioactivity was 4.07 +/- 0.1% (i.v.) and 6.78 +/- 0.2% (p.o.).,[Studies on metabolism and pharmacokinetics of alpha-acetyldigitoxin in man (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1242671/),%,6.78,226802,DB01396,Digitoxin
,1242671,protein binding,The protein binding of a 4%.,[Studies on metabolism and pharmacokinetics of alpha-acetyldigitoxin in man (author's transl)]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1242671/),%,4,226803,DB01396,Digitoxin
,1242671,Albumin solution,"Albumin solution was 83 +/- 0.54%, for plasma 80.8 +/- 2%.",[Studies on metabolism and pharmacokinetics of alpha-acetyldigitoxin in man (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1242671/),%,83,226804,DB01396,Digitoxin
,1242671,Albumin solution,"Albumin solution was 83 +/- 0.54%, for plasma 80.8 +/- 2%.",[Studies on metabolism and pharmacokinetics of alpha-acetyldigitoxin in man (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1242671/),%,80.8,226805,DB01396,Digitoxin
,8788139,Recoveries,"Recoveries of digoxin and its metabolites from serum ranged from 62 to 86%, and coefficients of variation from repetitive analyses ranged from 6.9 to 20.9% and from 5.8 to 12.2% at 0.5 ng ml-1 and 2.0 ng ml-1, respectively.",Specific and sensitive determination of digoxin and metabolites in human serum by high performance liquid chromatography with cyclodextrin solid-phase extraction and precolumn fluorescence derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8788139/),%,62 to 86,228248,DB01396,Digitoxin
,8788139,Recoveries,"Recoveries of digoxin and its metabolites from serum ranged from 62 to 86%, and coefficients of variation from repetitive analyses ranged from 6.9 to 20.9% and from 5.8 to 12.2% at 0.5 ng ml-1 and 2.0 ng ml-1, respectively.",Specific and sensitive determination of digoxin and metabolites in human serum by high performance liquid chromatography with cyclodextrin solid-phase extraction and precolumn fluorescence derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8788139/),%,6.9 to 20.9,228249,DB01396,Digitoxin
,7447220,elimination half-life,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),h,87.8,234262,DB01396,Digitoxin
,7447220,elimination half-life,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),h,218.3,234263,DB01396,Digitoxin
,7447220,total body clearance,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),[ml] / [h·kg],5.01,234264,DB01396,Digitoxin
,7447220,total body clearance,"In the presence of quinidine the serum digitoxin concentration was elevated, the mean digitoxin elimination half-life was increased from 87.8 +/- 11.6 to 218.3 +/- 20.6 h (mean +/- SEM) (p < 0.01), and mean total body clearance was reduced from 5.01 +/- 1.18 to 1.87 +/- 0.20 mL/h x kg (p < 0.052).",Digitoxin elimination reduced during quinidine therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7447220/),[ml] / [h·kg],1.87,234265,DB01396,Digitoxin
,3600823,half-life,The radioactivity remaining after 24 h was eliminated with a half-life of 219 h.,"Pharmacodynamics, pharmacokinetics and metabolism of digitoxin and derivatives in cats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3600823/),h,219,239757,DB01396,Digitoxin
,7212478,Elimination half-life,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),h,174,247882,DB01396,Digitoxin
,7212478,Elimination half-life,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),h,261,247883,DB01396,Digitoxin
,7212478,total body clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [h·kg],1.54,247884,DB01396,Digitoxin
,7212478,total body clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [h·kg],1.09,247885,DB01396,Digitoxin
,7212478,renal clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [h·kg],0.65,247886,DB01396,Digitoxin
,7212478,renal clearance,Quinidine induced the following changes in digitoxin pharmacokinetics: Elimination half-life was prolonged from 174 +/- 25 to 261 +/- 58 hours (p less than 0.02); total body clearance decreased from 1.54 +/- 0.40 to 1.09 +/- 0.31 mL/h . kg (p less than 0.05); renal clearance decreased from 0.65 +/- 0.07 to 0.46 +/- 0.17 mL/h . kg (p less than 0.05).,Digitoxin-quinidine interaction: pharmacokinetic evaluation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212478/),[ml] / [h·kg],0.46,247887,DB01396,Digitoxin
,16296683,half-life,The digitoxin half-life in elderly patients in the eight and ninth decade was more prolonged (mean +/- SD: 25 +/- 9 days) than in younger people (6.7 +/- 1.7).,Prolonged digitoxin half-life in very elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16296683/),d,25,251620,DB01396,Digitoxin
,16296683,half-life,The digitoxin half-life in elderly patients in the eight and ninth decade was more prolonged (mean +/- SD: 25 +/- 9 days) than in younger people (6.7 +/- 1.7).,Prolonged digitoxin half-life in very elderly patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16296683/),,6.7,251621,DB01396,Digitoxin
,6541927,intoxication rate,The intoxication rate lies between 4 and 6%.,[Gitoformate and digitoxin as alternatives to kidney-dependent glycosides in the therapy of cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6541927/),%,4 and 6,255135,DB01396,Digitoxin
,25864008,flow rate,Plasma samples were pretreated using a simple liquid-liquid extraction with ethyl acetate and the chromatographic separation of periplogenin and psoralen was achieved on a Waters XBridge™ BEH C18 column with 0.1% formic acid and acetonitrile as mobile phase at a flow rate of 0.4mL/min.,A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864008/),[ml] / [min],0.4,255347,DB01396,Digitoxin
,25864008,m/z,The optimized ion transition pairs for quantitation were m/z 391.3→m/z 337.2 for periplogenin and m/z 187.0→m/z 131.0 for IS.,A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864008/),,391.3,255348,DB01396,Digitoxin
,25864008,m/z,The optimized ion transition pairs for quantitation were m/z 391.3→m/z 337.2 for periplogenin and m/z 187.0→m/z 131.0 for IS.,A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864008/),→,187.0,255349,DB01396,Digitoxin
,25864008,m/z,The optimized ion transition pairs for quantitation were m/z 391.3→m/z 337.2 for periplogenin and m/z 187.0→m/z 131.0 for IS.,A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864008/),,131.0,255350,DB01396,Digitoxin
,25864008,total run time,The total run time was 9.0min.,A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864008/),min,9.0,255351,DB01396,Digitoxin
,25864008,recoveries,The average recoveries of periplogenin in plasma ranged from 85.1% to 95.6%.,A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864008/),%,85.1,255352,DB01396,Digitoxin
,25864008,recoveries,The average recoveries of periplogenin in plasma ranged from 85.1% to 95.6%.,A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25864008/),%,95.6,255353,DB01396,Digitoxin
,4064450,elimination half-life,"For digoxin, an unchanged elimination half-life (28 hours) and only slight increase in the total body clearance was found (from 203 to 204 ml/min).",Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064450/),h,28,257883,DB01396,Digitoxin
,4064450,total body clearance,"For digoxin, an unchanged elimination half-life (28 hours) and only slight increase in the total body clearance was found (from 203 to 204 ml/min).",Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064450/),[ml] / [min],203,257884,DB01396,Digitoxin
,4064450,total body clearance,"For digoxin, an unchanged elimination half-life (28 hours) and only slight increase in the total body clearance was found (from 203 to 204 ml/min).",Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064450/),[ml] / [min],204,257885,DB01396,Digitoxin
,4064450,elimination half-life,"There was a more pronounced effect on the kinetics of digitoxin, where the elimination half-life decreased from 4.3 to 3.6 days, and the total body clearance increased from 4.4 to 4.7 ml/min.",Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064450/),d,4.3 to 3.6,257886,DB01396,Digitoxin
,4064450,total body clearance,"There was a more pronounced effect on the kinetics of digitoxin, where the elimination half-life decreased from 4.3 to 3.6 days, and the total body clearance increased from 4.4 to 4.7 ml/min.",Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4064450/),[ml] / [min],4.4 to 4.7,257887,DB01396,Digitoxin
